Legal Counsel and Next Steps
Legal heavyweights are steering the cross-border transaction: Allen Overy Shearman Sterling is advising Ipsen, while Goodwin Procter LLP and Dentons are representing ImCheck and its shareholders.
Once finalized, the acquisition will make ImCheck a fully integrated part of Ipsen’s oncology research division, accelerating the company’s march into next-generation immunotherapies.
With €1 billion on the line, Ipsen’s bold move could redefine Europe’s footprint in the global cancer treatment race — a deal that transforms not just a portfolio, but potentially, the future of oncology innovation itself.
